Problemi non correnti
La displasia broncopolmonare e la sua gestione domiciliare
BRONCHOPULMONARY DYSPLASIA AND ITS HOME MANAGEMENT
LUCIANO ANFOSSI, STEFANIA FASSIO, ANNA RITA BERGHELLI
Struttura Complessa di Pneumologia, Ospedale Infantile Regina Margherita, Torino
Giugno 2007 - pagg. 375 -380
Abstract
Bronchopulmonary dysplasia (BPD) is considered one of the primary causes of chronic lung disease among infants. Pathogenesis is complex, being primarily influenced by prematurity, infection, supplementary oxygen and mechanical ventilation. Prevention involves appropriate care in order to avoid premature delivery, prenatal corticosteroids and surfactant replacement therapy. The in-hospital management of infants with BPD includes minimizing the duration of mechanical ventilation and avoiding the use of high ventilator settings and high inhaled oxygen concentrations. The primary care physician is involved in the management
of the infant with BPD as part of a multidisciplinary team. Oxygen, diuretic, bronchodilator,
anti-inflammatory, chest FKT and nutritional therapies are discussed in detail. Finally, current information on long-term prognosis and recommendations for the prevention of RSV infection
are reviewed.
Classificazione MeSH
Bibliografia
monary
disease following respiratory therapy
of hyaline-membrane disease. Bronchopulmonary
dysplasia. N Engl J Med 1967;276:
357-68.
2. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes oh Health Consensus Definition of Bronchopulmonary Dysplasia. Pediatrics 2005;116(6):1353-60.
3. Jobe AH, Bancalari E. Bronchopulmonary displasia. NICHD-NHLBI-ORD Workshop. Am J Resp Crit Care Med 2001;163:1723-9.
4. Walsh MC, Yao Q, Gettner P. Impact of a physiologic definition of bronchopulmonary dysplasia rates. Pediatrics 2004;114:1305-11.
5. Monte LF, Silva Filho LV, Miyoshi MH, Rozov T. Bronchopulmonary dysplasia. J Pediatr 2005;81(2):99-110.
6. Rossi UG, Owens CM. The radiology of chronic lung disease in children. Arch Dis Child 2005;90(6):601-7.
7. Schmidt B, Roberts RS, Davis P, Doyle LW. Caffeine therapy for apnoea of prematurity. N Engl J Med 2006;354:2112-21.
8. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2002;(4):CD000501.
9. Primhak RA. Discharge and aftercare in chronic lung disease of the newborn. Semin Neonatol 2003;8:117-25.
10. Nievas FF, Chernick V. Bronchopulmonary dysplasia: an update for the paediatrician. Clin Pediatr 2002;41:77-85.
11. Barrington KJ, Finer NN. Treatment of bronchopulmonary dysplasia. A review. Clin Perinatol 1998;25:177-202.
12. Rastogi A, Luayon M, Ajay OA, Pildes RS. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr 1994;125: 976-97.
13. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002;(1):CD 001817.
14. Kao LC, Durand DJ, McCrea RC, Birch M, Powers RJ, Nickerson BG. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr 1994;124(5):772-81.
15. Ng GY, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001;(3):CD003214.
16. De Boeck K, Smith J, Van Lierde S, Devlieger H. Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia. J Pediatr 1998;157: 75-9.
17. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1):CD001146.
18. American Academy of Pediatrics and Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109: 330-8.
19. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1): CD001145.
20. Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999;340:1005-10.
21. Pantalitschka T, Poets CF. Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia. Pediatr Pulmonol 2006; 41(8):703-8.
22. American Academy of Pediatrics. Prevention of respiratory syncytial virus infection: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102:1211-6.
23. Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network. Pediatrics 2001;107 (1):E1.
24. Greenough A. Measuring respiratory outcome. Semin.Neonatol 2000;5:119-26.
25. Gross SJ, Januzzi DM, Kveselis DA, Anbar RD. Effect of pre-term birth on pulmonary function at school age: a prospective controled study. J Pediatr 1998;133:188-92.
26. Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM. Bronchopulmonary dysplasia in very low birth weigt subjects and lung function in late adolescence. Pediatrics 2006;118(1):108-13.
2. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes oh Health Consensus Definition of Bronchopulmonary Dysplasia. Pediatrics 2005;116(6):1353-60.
3. Jobe AH, Bancalari E. Bronchopulmonary displasia. NICHD-NHLBI-ORD Workshop. Am J Resp Crit Care Med 2001;163:1723-9.
4. Walsh MC, Yao Q, Gettner P. Impact of a physiologic definition of bronchopulmonary dysplasia rates. Pediatrics 2004;114:1305-11.
5. Monte LF, Silva Filho LV, Miyoshi MH, Rozov T. Bronchopulmonary dysplasia. J Pediatr 2005;81(2):99-110.
6. Rossi UG, Owens CM. The radiology of chronic lung disease in children. Arch Dis Child 2005;90(6):601-7.
7. Schmidt B, Roberts RS, Davis P, Doyle LW. Caffeine therapy for apnoea of prematurity. N Engl J Med 2006;354:2112-21.
8. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2002;(4):CD000501.
9. Primhak RA. Discharge and aftercare in chronic lung disease of the newborn. Semin Neonatol 2003;8:117-25.
10. Nievas FF, Chernick V. Bronchopulmonary dysplasia: an update for the paediatrician. Clin Pediatr 2002;41:77-85.
11. Barrington KJ, Finer NN. Treatment of bronchopulmonary dysplasia. A review. Clin Perinatol 1998;25:177-202.
12. Rastogi A, Luayon M, Ajay OA, Pildes RS. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr 1994;125: 976-97.
13. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002;(1):CD 001817.
14. Kao LC, Durand DJ, McCrea RC, Birch M, Powers RJ, Nickerson BG. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr 1994;124(5):772-81.
15. Ng GY, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001;(3):CD003214.
16. De Boeck K, Smith J, Van Lierde S, Devlieger H. Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia. J Pediatr 1998;157: 75-9.
17. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1):CD001146.
18. American Academy of Pediatrics and Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109: 330-8.
19. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;(1): CD001145.
20. Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999;340:1005-10.
21. Pantalitschka T, Poets CF. Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia. Pediatr Pulmonol 2006; 41(8):703-8.
22. American Academy of Pediatrics. Prevention of respiratory syncytial virus infection: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102:1211-6.
23. Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network. Pediatrics 2001;107 (1):E1.
24. Greenough A. Measuring respiratory outcome. Semin.Neonatol 2000;5:119-26.
25. Gross SJ, Januzzi DM, Kveselis DA, Anbar RD. Effect of pre-term birth on pulmonary function at school age: a prospective controled study. J Pediatr 1998;133:188-92.
26. Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM. Bronchopulmonary dysplasia in very low birth weigt subjects and lung function in late adolescence. Pediatrics 2006;118(1):108-13.
Corrispondenza: lucianoanfossi@hotmail.it